Substance / Medication

Tetrahydrocannabinol

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

63 trials linked to this intervention

63
Total Trials
5
Recruiting
21
With Results

Research Evidence

Published studies and systematic reviews

Sort:
High-Concentration Delta-9-Tetrahydrocannabinol Cannabis Products and Mental Health Outcomes : A Systematic Review.
Rittiphairoj Thanitsara, Leslie Louis, Oberste Jean-Pierre et al. · Ann Intern Med · 2025
PMID: 40854216Meta-Analysis
Transcriptomic Alterations Induced by Tetrahydrocannabinol in SIV/HIV Infection: A Systematic Review.
Valizadeh Amir, Veenhuis Rebecca T, Bradley Brooklyn A et al. · Int J Mol Sci · 2025
PMID: 40141240Meta-AnalysisFull text (PMC)
Association of driving with blood delta-9-tetrahydrocannabinol: a systematic review.
Behzad Danial, Zhao Sampson, Besa Reena et al. · Int J Neuropsychopharmacol · 2025
PMID: 40172477Meta-AnalysisFull text (PMC)
The Pleiotropic Influence of Cannabidiol and Tetrahydrocannabinol on Inflammatory Biomarkers: A Systematic Review and Meta-Analytical Synthesis.
Candeloro Bruno Moreira, de Oliveira Camila M, Gimenez Fabiana Veronez Martelato et al. · Int J Mol Sci · 2025
PMID: 41373770Meta-AnalysisFull text (PMC)
Does acute cannabidiol (CBD) use impair performance? A meta-analysis and comparison with placebo and delta-9-tetrahydrocannabinol (THC).
Lo Lindsay A, Christiansen April L, Strickland Justin C et al. · Neuropsychopharmacology · 2024
PMID: 38528133Meta-AnalysisFull text (PMC)
A Systematic Review of Delta-9-Tetrahydrocannabinol (∆9-THC) in Astrocytic Markers.
Ramos-Jiménez Christian, Petkau Sarah, Mizrahi Romina · Cells · 2024
PMID: 39404391Meta-AnalysisFull text (PMC)
Systematic review of drug-drug interactions of delta-9-tetrahydrocannabinol, cannabidiol, and.
Nachnani Rahul, Knehans Amy, Neighbors Jeffrey D et al. · Front Pharmacol · 2024
PMID: 38868665Meta-AnalysisFull text (PMC)
The effect of tetrahydrocannabinol:cannabidiol oromucosal spray on cognition: a systematic review.
Motaghi Ehsan, Ghasemi-Pirbaluti Masoumeh, Rashidi Mohsen et al. · Eur J Clin Pharmacol · 2023
PMID: 36700997Meta-Analysis
Using the BMD Approach to Derive Acceptable Daily Intakes of Cannabidiol (CBD) and Tetrahydrocannabinol (THC) Relevant to Electronic Cigarette Liquids.
Hindelang Pascal, Scharinger Andreas, Richling Elke et al. · Front Biosci (Landmark Ed) · 2022
PMID: 36042166Meta-Analysis

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Tetrahydrocannabinol (substance)
SNOMED CT
72024007
UMLS CUI
C0039663

Clinical Data

This intervention maps to 1 entities in the Healos knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
63
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.